Effects of l-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients

Background. Carnitine loss through dialysis membranes is shown to be related to the lack of carnitine in long-term haemodialysis patients. It has been previously reported that haemodialysis patients might have benefited from carnitine supplementation. Methods. A total of 21 chronic haemodialysis pat...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2006-11, Vol.21 (11), p.3211-3214
Main Authors: Duranay, Murat, Akay, Hatice, Yilmaz, Fatma Meriç, Şeneş, Mehmet, Tekeli, Nurçin, Yücel, Doğan
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Biomarkers - blood
Blood Proteins - metabolism
C-Reactive Protein - biosynthesis
C-Reactive Protein - metabolism
Carnitine - administration & dosage
Carnitine - blood
Carnitine - physiology
CRP
Emergency and intensive care: renal failure. Dialysis management
Female
Glomerulonephritis
haemodialysis
Humans
Incidence
inflammation
Inflammation Mediators - blood
Infusions, Intravenous
Intensive care medicine
l-carnitine
Lipids - blood
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
nutrition
Nutritional Status
Pharmacology. Drug treatments
Renal Dialysis
Serum Albumin - metabolism
Transferrin - metabolism
Urinary system
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Carnitine loss through dialysis membranes is shown to be related to the lack of carnitine in long-term haemodialysis patients. It has been previously reported that haemodialysis patients might have benefited from carnitine supplementation. Methods. A total of 21 chronic haemodialysis patients maintaining carnitine supplementation and 21 controls (haemodialysis patients not receiving carnitine) were included in the study. l-carnitine was used intravenously three times a week after each haemodialysis session, at a 20 mg/kg dose. C-reactive protien (CRP), lipid profile, transferrin, total protein and albumin levels were determined at baseline after 3 and 6 months of treatment, and compared with the control group. Results. CRP levels were significantly decreased in carnitine group in contrast to the increase in the control group. Transferrin, total protein and albumin levels and body mass index (BMI) of the patients rose in the carnitine group. Conclusions. There was a significant benefit of l-carnitine on CRP, transferrin, total protein and albumin levels of the haemodialysis patients.
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfl356